A team of our own "doctors" will be at the ISPE Annual Meeting. Will you?

We’re excited to be joining 1,000 of our pharmaceutical colleagues at the upcoming ISPE Annual Meeting, to take place Nov. 6-9 in Grapevine, Texas. Themed “Preparing Professionals and Organizations for Rapid Change,” this is an opportunity for pharma pros from around the world to collaborate, learn and prepare for the widespread changes happening in the pharmaceutical industry.

There are five educational tracks — manufacturing, technology, regulations, facilities and investigational products — that will focus on facility delivery challenges, manufacturing problems, project and operational risks, regulatory uncertainties, technological changes, and global diversification. The entire conference promises to be chock-full of valuable pharmaceutical information, but we’re especially looking forward to the keynote session with four industry experts who will share their thoughts on the state of the industry.

Timothy C. Tyson, chairman and CEO of Aptuit Inc., will present his vision for the future of the industry and discuss the importance of leadership roles in incorporating technology to make his vision a reality.

Brett P. Giroir, vice chancellor for strategic initiatives for the Texas A&M University system, will focus on three factors that have challenged the traditional paradigm for vaccine biotherapeutics development: emerging infectious diseases that require a low-cost, rapid-response solution; a reduction in the number of viable candidates for clinical trials; and the rapid progress in personalized therapeutics. He’ll also discuss how his team responded to these challenges.

John Menna, director for healthcare strategy at UPS, will share how his company is dealing with biotechnology and pharmaceutical products supply chain challenges, including global sourcing, increasing levels of third-party manufacturing, theft and counterfeiting, and environmental risks.

J. David Doleski, acting director for the Division of Good Manufacturing Practices Assessment in the Office of Compliance, Center for Drug Evaluation and Research for the FDA, will share some of his agency’s priorities and initiatives on pharmaceutical quality and the impact that manufacturing trends will have on regulators, manufacturers and patients.

Are any of our readers also attending? We’d love to hear which sessions you’re most excited about. Be sure to stop by our booth (#743) and say hello if you’re in the exhibit area. If the opportunity to meet with one of our very own “doctors” isn’t enough reason to visit, you can also register to win a free iPad. We hope to see you there!

by